ValorQ4, 24Q1, 25Q2, 25Q3, 25TTMGastos comerciales, generales y administrativos333.88 M353.8 M349.7 M352.3 M1.39 BInvestigación y desarrollo27.65 M26.4 M28.2 M29.5 M111.75 MBeneficio operativo216.14 M246 M265.8 M273.2 M1 BTotal de ingresos no operativos-18.83 M-14.1 M-12.7 M-15.3 M-60.93 MGastos por intereses, netos de intereses capitalizados17.06 M15.9 M14.9 M14.9 M62.76 MIngresos no operativos, una vez deducidos los gastos por intereses-39.5 M-31.8 M-30 M-33.1 M-134.4 MIngresos/gastos extraordinarios3.6 M1.8 M2.4 M2.9 M10.7 MBeneficio antes de impuestos197.41 M231.9 M253.1 M257.8 M940.21 MParticipación en los beneficios—————Impuestos50.45 M53.9 M60.6 M63.5 M228.45 MParticipación minoritaria433 K600 K600 K1.5 M3.13 MOtros ingresos/gastos después de impuestos-3.46 M-14.5 M1.3 M1 M-15.65 MBeneficio neto antes de actividades interrumpidas146.52 M177.4 M191.9 M192.9 M708.72 MOperaciones suspendidas-783 K000-783 KBeneficio neto145.74 M177.4 M191.9 M192.9 M707.94 MAjuste por dilución—————Dividendos de las acciones preferentes—————Beneficio neto diluido atribuible a los accionistas145.74 M177.4 M191.9 M192.9 M707.94 MBeneficio básico por acción1.491.81.951.967.2Beneficio por acción diluido1.481.791.941.967.17Número medio de acciones ordinarias98.58 M98.4 M98.4 M98.2 M393.57 MAcciones diluidas99.07 M98.8 M98.8 M98.6 M395.27 MEBITDA1.18 B365.4 M387.5 M395.2 M2.33 BEBIT1.06 B246 M265.8 M273.2 M1.84 BCosto de los ingresos—763.1 M814.4 M840.7 M—Otros costes de producción—————Amortización y depreciación (flujo de caja)122.31 M119.4 M121.7 M122 M485.42 M
STERIS plc (Ireland)
Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.
Steris is listed on the New York Stock Exchange, and is a constituent of the S&P 500 Index. As of 2024, the President and CEO is Daniel A. Carestio.